Adient (ADNT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual general meeting is scheduled for March 11, 2025, in Dublin, Ireland, with eight directors up for election and several key proposals on the agenda.
Shareholders can vote on director elections, auditor ratification, executive compensation, incentive plan amendments, and board authorities under Irish law.
Proxy materials are available online, and shareholders are encouraged to vote electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposals include electing eight directors, ratifying PricewaterhouseCoopers LLP as auditor, approving executive compensation, amending the 2021 Omnibus Incentive Plan, renewing board authority to issue shares, and opting out of statutory preemption rights.
Most proposals require a simple majority, except the opt-out of preemption rights, which needs 75% approval.
Shareholders may submit director nominations and proposals for the 2026 meeting within specified timeframes.
Board of directors and corporate governance
The board will reduce to eight members, with 89% independence and 55% gender or ethnic diversity.
Chair and CEO roles are separated, with an independent chair.
Committees (Audit, Human Capital and Compensation, Corporate Governance) are fully independent.
Annual board, committee, and director evaluations are conducted.
Proxy access rights are granted to shareholders.
Latest events from Adient
- Q1 FY26 saw 4% revenue growth and raised guidance, driven by China, innovation, and new wins.ADNT
Q1 20264 Feb 2026 - Disciplined capital allocation, innovation, and regional growth drive margin expansion and value.ADNT
Deutsche Bank Global Auto Industry Conference 20253 Feb 2026 - Margin expansion and innovation drive growth, with China focus and restructuring prioritized.ADNT
J.P. Morgan Auto Conference 20242 Feb 2026 - Q3 sales dropped 8% and net loss hit $11M, but cash flow and buybacks stayed strong.ADNT
Q3 20242 Feb 2026 - Proxy covers director elections, auditor ratification, compensation, and share issuance authority.ADNT
Proxy Filing21 Jan 2026 - Director elections, auditor ratification, and Board authority renewals up for shareholder vote.ADNT
Proxy Filing21 Jan 2026 - Margin expansion and strong cash flow in FY24, with China and EMEA as key focus areas.ADNT
Q4 202415 Jan 2026 - Q1 FY2025: $196M EBITDA, $45M cash flow, EMEA weak, guidance trimmed, liquidity strong.ADNT
Q1 20259 Jan 2026 - Shareholders will vote on director elections, auditor ratification, and key governance proposals.ADNT
Proxy Filing1 Dec 2025